PATENT BOOST FOR MEDIGARD

Written on the 13 October 2010 by Tom Reid

PATENT BOOST FOR MEDIGARD

MEDIGARD Limited (MGZ) has received a huge boost in its prospects for distributing a second product into the United States following a patent approval in South Africa.

The publically-listed medical tech company’s 3ml retractable syringe has today been granted exclusive patent protection in the African republic until 2027.

CEO Peter Emery says South Africa is not a priority market and the approval ‘came out of the blue’, but the development bodes well for a successful application in the United States.

Medigard recently cracked the US market after signing a manufacturing and distribution deal for its innovative blood collection device (BCD).

Following a successful US Food and Drug Administration (FDA) application, the BCD distributor Outcome Solutions would have first rights to the retractable syringe.

“The BCD is the first Medigard product and is absolutely ready to go, whereas the 3ml retractable syringe is a little behind in development,” says Emery.

“But it is a key product and patent approval in South Africa is a positive indicator that the application will also be successful in other markets. We apply for patents on our products in multi-jurisdictions; it just so happens that South Africa was the first to approve it.”

While the priority won’t shift away from the United States, Emery says the approval furthers Medigard’s long-term prospects.

“It is a global plan and South Africa being a developed nation is a viable market for us,” he says.

“The rest of Africa is a more interesting market in that it’s less developed, but in great need of our retractable syringe product that stops the spread of Aids caused by reusing syringes.

“The big challenge however is that there is no money in these regions for manufacturing and distribution. For this type of product to work in all the African markets it would take the United Nations or a similar humanitarian group to provide the funding to get them to all the districts and villages.”

After launching a capital raising venture in the form of a shareholder rights issue, Medigard is still around $600,000 short of the $1.57 million required to get the first run of US manufacturing underway.

Emery says the company is exploring all avenues available to it in order to raise the additional funding.


Author: Tom Reid

Latest News

ASF UNVEILS TRAFFIC PLANS FOR THE SPIT

A SECOND bridge over the Nerang River is the centrepiece of the ASF Consortium's plan to improve traffic flow ...

BHP AND VALE EDGE CLOSER TO $47.5 BILLION SAMARCO DAM DISASTER SETTLEMENT

BHP Billiton (ASX: BHP) and Brazilian mining company Vale have entered into a preliminary agreement with Brazilian fe...

BLK SPORT FOUNDER TYRON BRANT REMAINS CEO UNDER NEW OWNERS

BLK Sport has been purchased from receivers McGrathNicol by a private consortium composed of a TimorLeste-based oi...

CARSALES CEO RETIRES AS NEW COMPETITOR COX FINALISES MERGER

CARSALES will have a new CEO as it takes on a fresh challenger to its crown as the dominant online car sales portal i...

Related News

CARSALES CEO RETIRES AS NEW COMPETITOR COX FINALISES MERGER

CARSALES will have a new CEO as it takes on a fresh challenger to its crown as the dominant online car sales portal i...

BUSINESS CONFIDENCE AT A SIX-YEAR HIGH

SMALL and medium businesses have entered 2017 with their confidence at a six-year high, building on strong gains m...

CONSUMERS PESSIMISTIC ENTERING 2017

CONSUMER confidence remains at its weakest point since April 2016, according to the latest Westpac Melbourne Institut...

RISE OF STARTUP SUPPORT PROGRAMS NOT AS ROSY AT IT SEEMS

ENTREPRENEURIAL cultivation companies in Australia are appearing quickly, but questions have been raised about whe...

Contact us

Email News Update Sign Up Contact Details
Subscriptions

PO Box 2087
Brisbane QLD 4001

LoginTell a FriendSign Up to Newsletter